- Home
- ALIT vs VRNA Comparison
ALIT vs VRNA Comparison
Compare ALIT & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALIT
- VRNA
- Stock Information
- Founded
- ALIT 2017
- VRNA 2005
- Country
- ALIT United States
- VRNA United Kingdom
- Employees
- ALIT N/A
- VRNA N/A
- Industry
- ALIT Business Services
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- ALIT Consumer Discretionary
- VRNA Health Care
- Exchange
- ALIT Nasdaq
- VRNA Nasdaq
- Market Cap
- ALIT 3.7B
- VRNA 3.4B
- IPO Year
- ALIT N/A
- VRNA 2017
- Fundamental
- Price
- ALIT $6.63
- VRNA $61.20
- Analyst Decision
- ALIT Strong Buy
- VRNA Strong Buy
- Analyst Count
- ALIT 9
- VRNA 7
- Target Price
- ALIT $10.61
- VRNA $53.14
- AVG Volume (30 Days)
- ALIT 5.1M
- VRNA 1.6M
- Earning Date
- ALIT 02-19-2025
- VRNA 02-27-2025
- Dividend Yield
- ALIT 0.60%
- VRNA N/A
- EPS Growth
- ALIT N/A
- VRNA N/A
- EPS
- ALIT N/A
- VRNA N/A
- Revenue
- ALIT $3,358,000,000.00
- VRNA $5,624,000.00
- Revenue This Year
- ALIT N/A
- VRNA N/A
- Revenue Next Year
- ALIT $3.30
- VRNA $568.20
- P/E Ratio
- ALIT N/A
- VRNA N/A
- Revenue Growth
- ALIT 26.91
- VRNA 1127.95
- 52 Week Low
- ALIT $6.15
- VRNA $11.39
- 52 Week High
- ALIT $10.38
- VRNA $60.81
- Technical
- Relative Strength Index (RSI)
- ALIT 39.16
- VRNA 73.33
- Support Level
- ALIT $6.49
- VRNA $55.42
- Resistance Level
- ALIT $7.03
- VRNA $60.81
- Average True Range (ATR)
- ALIT 0.15
- VRNA 2.84
- MACD
- ALIT -0.00
- VRNA 0.41
- Stochastic Oscillator
- ALIT 27.78
- VRNA 92.93
About ALIT Alight Inc.
Alight Inc is a provider of integrated, cloud-based human capital solutions that empower clients and employees to manage health, wealth and HR needs. Geographically, the company generates a majority of its revenue from the United States.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.